ABSI vs REGN

Absci maintains its position as a high-risk, high-reward opportunity due to its innovative AI-powered drug discovery platform targeting a massive TAM. The integrated AI/wet-lab approach, coupled with proprietary data and ongoing strategic partnerships, provides a compelling competitive edge with significant scalability potential. The technological promise for 10x growth remains strong, driven by t...

Regeneron is a high-quality, profitable pharmaceutical giant with robust R&D and strong market positions (e.g., Dupixent). However, its substantial current market capitalization (over $80B) and established, albeit growing, business model make 10x growth within 3-5 years highly improbable. Its catalysts, while significant for continued strong performance, are incremental rather than disruptive enou...